Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.10 Bn | 625.34 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 441.68 Bn | 435.11 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 366.62 Bn | 359.48 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn | -19.23% |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | -108.13% |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 8 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | 44.59% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 7.59% |
| 10 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | 34.33% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34.33% |
| Mar 31, 2026 | 2,405.06% |
| Dec 31, 2025 | 49.08% |
| Sep 30, 2025 | 61.40% |
| Jun 30, 2025 | 65.38% |
| Mar 31, 2025 | -81.80% |
| Dec 31, 2024 | -30.20% |
| Sep 30, 2024 | 56.20% |
| Jun 30, 2024 | -31.94% |
| Mar 31, 2024 | 156.66% |
| Dec 31, 2023 | 65.96% |
| Sep 30, 2023 | 21.31% |
| Jun 30, 2023 | 665.09% |
| Mar 31, 2023 | -651.08% |
| Dec 31, 2022 | 1,319.18% |
| Sep 30, 2022 | 204.44% |
| Jun 30, 2022 | -139.95% |
| Mar 31, 2022 | -56.70% |
| Dec 31, 2021 | -102.10% |
| Sep 30, 2021 | 139.06% |